Calithera Biosciences Stock Price, News & Analysis (NASDAQ:CALA)

$9.50 -0.20 (-2.06 %)
(As of 12/11/2017 02:43 AM ET)
Previous Close$9.70
Today's Range$9.45 - $9.80
52-Week Range$3.00 - $20.05
Volume427,800 shs
Average Volume740,981 shs
Market Capitalization$337.03 million
P/E RatioN/A
Dividend YieldN/A
Beta2.89

About Calithera Biosciences (NASDAQ:CALA)

Calithera Biosciences logoCalithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.

Receive CALA News and Ratings via Email

Sign-up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CALA
CUSIPN/A
Phone+1-650-8701000

Debt

Debt-to-Equity RatioN/A
Current Ratio4.60%
Quick Ratio4.60%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.29 per share
Price / Book4.15

Profitability

Trailing EPS($0.99)
Net Income$-38,000,000.00
Net MarginsN/A
Return on Equity-19.67%
Return on Assets-15.11%

Miscellaneous

Employees50
Outstanding Shares35,480,000

Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences Inc (NASDAQ:CALA) posted its quarterly earnings data on Thursday, November, 2nd. The biotechnology company reported ($0.17) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.06. The biotechnology company had revenue of $7.20 million for the quarter, compared to analysts' expectations of $6.02 million. View Calithera Biosciences' Earnings History.

Where is Calithera Biosciences' stock going? Where will Calithera Biosciences' stock price be in 2017?

6 brokers have issued 12 month target prices for Calithera Biosciences' stock. Their predictions range from $5.00 to $20.00. On average, they anticipate Calithera Biosciences' stock price to reach $14.40 in the next year. View Analyst Ratings for Calithera Biosciences.

What are Wall Street analysts saying about Calithera Biosciences stock?

Here are some recent quotes from research analysts about Calithera Biosciences stock:

  • 1. According to Zacks Investment Research, "Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company's lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California. " (11/6/2017)
  • 2. JMP Securities analysts commented, "Calithera Biosciences reports achievement of PK and PD goals in the Phase I trial of CB-1158, which entitles the company to receive a $12MM milestone payment as per its collaboration agreement with Incyte (INCY, MO, PT UR, Bayko); reiterate our Market Outperform rating and $12 price target based on a synthesis of our DCF, SOTP, and comparable company valuation methodologies. We view this early milestone achievement as further validation of the company's collaboration with INCY as well as of the subject of the agreement, CB-1158, a first-in-class arginase inhibitor and potential immunotherapeutic. CB-1158 has thus far demonstrated favorable pharmacologic activity in human subjects, with elevated plasma arginine levels consistent with those seen in preclinical cancer models. We remind investors that additional clinical data for CB-1158 in the setting of immuno-oncology are expected in mid-2017." (3/28/2017)

Who are some of Calithera Biosciences' key competitors?

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the folowing people:

  • Susan M. Molineaux Ph.D., President, Chief Executive Officer, Co-Founder, Director (Age 63)
  • Curtis C. Hecht, Senior Vice President - Business and Corporate Development (Age 46)
  • Christopher J. Molineaux Ph.D., Senior Vice President - Development (Age 63)
  • Keith Orford M.D. Ph.D., Senior Vice President, Clinical Development (Age 45)
  • Eric B. Sjogren Ph.D., Senior Vice President - Drug Discovery (Age 60)
  • Stephanie Wong, Vice President - Finance, Secretary (Age 43)
  • Francesco Parlati Ph.D., Vice President - Research
  • Deepika R. Pakianathan Ph.D., Lead Independent Director (Age 52)
  • Sunil Agarwal M.D., Independent Director (Age 47)
  • Jonathan G. Drachman M.D., Independent Director (Age 55)

Who owns Calithera Biosciences stock?

Calithera Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include American Century Companies Inc. (1.20%), Candriam Luxembourg S.C.A. (0.62%), Artal Group S.A. (0.49%), ClariVest Asset Management LLC (0.14%), California State Teachers Retirement System (0.14%) and California Public Employees Retirement System (0.12%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp, LL, Curtis Hecht and Keith Orford. View Institutional Ownership Trends for Calithera Biosciences.

Who sold Calithera Biosciences stock? Who is selling Calithera Biosciences stock?

Calithera Biosciences' stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Candriam Luxembourg S.C.A., Artal Group S.A., California State Teachers Retirement System and ClariVest Asset Management LLC. Company insiders that have sold Calithera Biosciences company stock in the last year include Adage Capital Partners Gp, LL, Curtis Hecht and Keith Orford. View Insider Buying and Selling for Calithera Biosciences.

Who bought Calithera Biosciences stock? Who is buying Calithera Biosciences stock?

Calithera Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., California Public Employees Retirement System, Dupont Capital Management Corp, State Board of Administration of Florida Retirement System, Dynamic Technology Lab Private Ltd, Trexquant Investment LP and Wells Fargo & Company MN. View Insider Buying and Selling for Calithera Biosciences.

How do I buy Calithera Biosciences stock?

Shares of Calithera Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Calithera Biosciences' stock price today?

One share of Calithera Biosciences stock can currently be purchased for approximately $9.50.

How big of a company is Calithera Biosciences?

Calithera Biosciences has a market capitalization of $337.03 million. The biotechnology company earns $-38,000,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Calithera Biosciences employs 50 workers across the globe.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 Oyster Point Blvd # 200, SOUTH SAN FRANCISCO, CA 94080-1913, United States. The biotechnology company can be reached via phone at +1-650-8701000 or via email at [email protected]


MarketBeat Community Rating for Calithera Biosciences (CALA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  140 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Calithera Biosciences (NASDAQ:CALA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.802.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.40$14.40$14.40$14.00
Price Target Upside: 9.15% downside9.15% downside1.41% upside1.41% downside

Calithera Biosciences (NASDAQ:CALA) Consensus Price Target History

Price Target History for Calithera Biosciences (NASDAQ:CALA)

Calithera Biosciences (NASDAQ:CALA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/5/2017William BlairInitiated CoverageOutperform -> OutperformN/AView Rating Details
6/12/2017HC WainwrightReiterated RatingBuy$14.00 -> $19.00LowView Rating Details
6/6/2017Wells Fargo & CompanyReiterated RatingOutperform$15.00 -> $20.00HighView Rating Details
4/3/2017Leerink SwannReiterated RatingOutperform -> Outperform$16.00MediumView Rating Details
3/28/2017JMP SecuritiesReiterated RatingOutperform$12.00 -> $12.00MediumView Rating Details
1/24/2017CitigroupUpgradeSell -> Neutral$5.00N/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$20.00 -> $12.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Calithera Biosciences (NASDAQ:CALA) Earnings History and Estimates Chart

Earnings by Quarter for Calithera Biosciences (NASDAQ:CALA)

Calithera Biosciences (NASDAQ CALA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.23)($0.17)$6.02 million$7.20 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.29)($0.15)$4.80 million$7.26 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.36)($0.22)$1.40 million$4.19 millionViewListenView Earnings Details
3/16/2017Q4 2016($0.48)($0.45)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.47)($0.44)ViewListenView Earnings Details
8/9/2016Q2($0.52)($0.55)ViewListenView Earnings Details
5/10/2016Q1($0.47)($0.52)ViewListenView Earnings Details
3/15/2016Q415($0.56)($0.44)ViewListenView Earnings Details
11/9/2015Q3($0.52)($0.49)ViewListenView Earnings Details
8/10/2015Q215($0.45)($0.44)ViewListenView Earnings Details
11/14/2014Q3 2014($0.28)($16.85)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Calithera Biosciences (NASDAQ:CALA) Earnings Estimates

2017 EPS Consensus Estimate: ($0.60)
2018 EPS Consensus Estimate: ($0.98)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.17)($0.17)($0.17)
Q3 20172($0.27)($0.17)($0.22)
Q4 20172($0.23)($0.19)($0.21)
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.23)($0.23)($0.23)
Q3 20181($0.25)($0.25)($0.25)
Q4 20181($0.29)($0.29)($0.29)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Calithera Biosciences (NASDAQ:CALA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Calithera Biosciences (NASDAQ CALA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.30%
Institutional Ownership Percentage: 72.19%
Insider Trades by Quarter for Calithera Biosciences (NASDAQ:CALA)
Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)

Calithera Biosciences (NASDAQ CALA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2017Adage Capital Partners Gp, L.LMajor ShareholderSell576,000$15.64$9,008,640.00View SEC Filing  
7/17/2017Keith OrfordVPSell2,120$18.31$38,817.20View SEC Filing  
7/6/2017Curtis HechtSVPSell700$18.00$12,600.00View SEC Filing  
5/19/2017Curtis HechtSVPSell650$16.00$10,400.00View SEC Filing  
3/22/2017Adage Capital Partners Gp, L.LMajor ShareholderBuy487,804$10.25$4,999,991.00View SEC Filing  
3/13/2017Curtis HechtSVPSell600$14.00$8,400.00View SEC Filing  
11/16/2016Adage Capital Partners Gp, L.LMajor ShareholderBuy500,000$3.15$1,575,000.00View SEC Filing  
11/16/2015Curtis HechtVPSell970$6.58$6,382.60View SEC Filing  
9/23/2015Adage Capital Partners Gp LlcMajor ShareholderBuy106,968$6.03$645,017.04View SEC Filing  
9/4/2015Adage Capital Partners Gp LlcMajor ShareholderBuy90,300$5.93$535,479.00View SEC Filing  
8/28/2015Adage Capital Partners Gp LlcMajor ShareholderBuy172,126$5.27$907,104.02View SEC Filing  
10/15/2014Adage Capital Partners Gp LlcMajor ShareholderBuy181,700$6.96$1,264,632.00View SEC Filing  
10/7/2014Jean GeorgeDirectorBuy300,000$10.00$3,000,000.00View SEC Filing  
10/7/2014Morgenthaler Venture PartnersMajor ShareholderBuy350,000$10.00$3,500,000.00View SEC Filing  
10/1/2014Adage Capital Partners Gp LlcMajor ShareholderBuy800,000$10.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Calithera Biosciences (NASDAQ CALA) News Headlines

Source:
DateHeadline
Calithera Biosciences (CALA) Lowered to Strong Sell at BidaskClubCalithera Biosciences (CALA) Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - December 9 at 10:36 AM
Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer SymposiumUpdated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium
finance.yahoo.com - December 5 at 10:25 AM
ValuEngine Lowers Calithera Biosciences (CALA) to SellValuEngine Lowers Calithera Biosciences (CALA) to Sell
www.americanbankingnews.com - December 3 at 8:44 PM
Calithera Biosciences, Inc. (CALA) Receives Average Recommendation of "Buy" from AnalystsCalithera Biosciences, Inc. (CALA) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 30 at 9:56 PM
 Brokerages Anticipate Calithera Biosciences, Inc. (CALA) Will Announce Quarterly Sales of $7.28 Million Brokerages Anticipate Calithera Biosciences, Inc. (CALA) Will Announce Quarterly Sales of $7.28 Million
www.americanbankingnews.com - November 27 at 2:30 PM
Comparing Rigel Pharmaceuticals (RIGL) & Calithera Biosciences (CALA)Comparing Rigel Pharmaceuticals (RIGL) & Calithera Biosciences (CALA)
www.americanbankingnews.com - November 25 at 11:34 AM
Interesting CALA Put And Call Options For January 2018Interesting CALA Put And Call Options For January 2018
www.thestreet.com - November 21 at 5:08 PM
Calithera Sell-Off Unwarranted as Investors Ignore Positive Signal in Upcoming Breast Cancer DataCalithera Sell-Off Unwarranted as Investors Ignore Positive Signal in Upcoming Breast Cancer Data
finance.yahoo.com - November 16 at 5:20 PM
Calithera Biosciences Inc. (CALA) Sank To A 6-Month LowCalithera Biosciences Inc. (CALA) Sank To A 6-Month Low
www.rttnews.com - November 14 at 5:25 PM
Research Analysts Issue Forecasts for Calithera Biosciences, Inc.s Q1 2018 Earnings (CALA)Research Analysts Issue Forecasts for Calithera Biosciences, Inc.'s Q1 2018 Earnings (CALA)
www.americanbankingnews.com - November 10 at 10:50 AM
Calithera Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : CALA-US : November 8, 2017Calithera Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : CALA-US : November 8, 2017
finance.yahoo.com - November 8 at 7:49 PM
$7.28 Million in Sales Expected for Calithera Biosciences, Inc. (CALA) This Quarter$7.28 Million in Sales Expected for Calithera Biosciences, Inc. (CALA) This Quarter
www.americanbankingnews.com - November 8 at 6:32 AM
Calithera Biosciences (CALA) Says Initial Results from Phase 2 ... - StreetInsider.comCalithera Biosciences (CALA) Says Initial Results from Phase 2 ... - StreetInsider.com
www.streetinsider.com - November 8 at 5:55 AM
Initial Results from Phase 2 Study of CB-839 in Combination with Opdivo® (nivolumab) to be Presented at the Society for Immunotherapy of Cancer MeetingInitial Results from Phase 2 Study of CB-839 in Combination with Opdivo® (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting
finance.yahoo.com - November 7 at 7:51 PM
Is Calithera Biosciences Inc (CALA) Undervalued?Is Calithera Biosciences Inc (CALA) Undervalued?
finance.yahoo.com - November 7 at 7:51 PM
Calithera Biosciences, Inc. (CALA) Upgraded to Buy at Zacks Investment ResearchCalithera Biosciences, Inc. (CALA) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - November 6 at 6:14 PM
Calithera Biosciences, Q3 Analysis, Analysts Target and Clinical Trials ReviewCalithera Biosciences, Q3 Analysis, Analysts Target and Clinical Trials Review
finance.yahoo.com - November 6 at 6:02 PM
 Brokerages Expect Calithera Biosciences, Inc. (CALA) Will Announce Earnings of -$0.24 Per Share Brokerages Expect Calithera Biosciences, Inc. (CALA) Will Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - November 6 at 3:06 PM
Leerink Swann Comments on Calithera Biosciences, Inc.s FY2017 Earnings (CALA)Leerink Swann Comments on Calithera Biosciences, Inc.'s FY2017 Earnings (CALA)
www.americanbankingnews.com - November 6 at 7:14 AM
Calithera Biosciences, Inc. (CALA) Given Average Recommendation of "Buy" by AnalystsCalithera Biosciences, Inc. (CALA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 5 at 7:32 PM
Calithera Biosciences Reports Third Quarter 2017 Financial Results ... - NasdaqCalithera Biosciences Reports Third Quarter 2017 Financial Results ... - Nasdaq
www.nasdaq.com - November 4 at 11:45 PM
Calithera Biosciences, Inc. (CALA) Announces  Earnings ResultsCalithera Biosciences, Inc. (CALA) Announces Earnings Results
www.americanbankingnews.com - November 3 at 9:31 PM
Calithera Biosciences Reports Third Quarter 2017 Financial Results and Recent Highlights - GlobeNewswire (press release)Calithera Biosciences Reports Third Quarter 2017 Financial Results and Recent Highlights - GlobeNewswire (press release)
globenewswire.com - November 3 at 8:09 AM
Calithera Biosciences Reports Third Quarter 2017 Financial Results and Recent HighlightsCalithera Biosciences Reports Third Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - November 2 at 5:37 PM
Calithera reports 3Q lossCalithera reports 3Q loss
finance.yahoo.com - November 2 at 5:37 PM
Calithera Biosciences, Inc. (CALA) Scheduled to Post Earnings on TuesdayCalithera Biosciences, Inc. (CALA) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:08 AM
Calithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : October 24, 2017Calithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : October 24, 2017
finance.yahoo.com - October 24 at 7:08 PM
Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with KeytrudaCalithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda
finance.yahoo.com - October 19 at 5:24 PM
Calithera Biosciences, Inc. (CALA) Expected to Post Quarterly Sales of $6.03 MillionCalithera Biosciences, Inc. (CALA) Expected to Post Quarterly Sales of $6.03 Million
www.americanbankingnews.com - October 19 at 1:46 AM
Head to Head Comparison: Calithera Biosciences (CALA) vs. The CompetitionHead to Head Comparison: Calithera Biosciences (CALA) vs. The Competition
www.americanbankingnews.com - October 18 at 8:20 PM
Calithera Biosciences, Inc. (CALA) Expected to Post Earnings of -$0.25 Per ShareCalithera Biosciences, Inc. (CALA) Expected to Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - October 17 at 10:26 PM
Surging Earnings Estimates Signal Good News for Calithera Biosciences (CALA) - NasdaqSurging Earnings Estimates Signal Good News for Calithera Biosciences (CALA) - Nasdaq
www.nasdaq.com - October 13 at 10:31 PM
Calithera Biosciences, Inc. (CALA) Receives Consensus Recommendation of "Buy" from BrokeragesCalithera Biosciences, Inc. (CALA) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 11 at 10:32 PM
Calithera Biosciences, Inc. (CALA) Expected to Post Q3 2017 Earnings of ($0.17) Per ShareCalithera Biosciences, Inc. (CALA) Expected to Post Q3 2017 Earnings of ($0.17) Per Share
www.americanbankingnews.com - October 9 at 2:34 AM
DURECT Corporation (DRRX) vs. Calithera Biosciences (CALA) Critical SurveyDURECT Corporation (DRRX) vs. Calithera Biosciences (CALA) Critical Survey
www.americanbankingnews.com - October 6 at 2:12 PM
Calithera Biosciences Inc (CALA) Research Coverage Started at William BlairCalithera Biosciences Inc (CALA) Research Coverage Started at William Blair
www.americanbankingnews.com - October 5 at 5:36 PM
Calithera Biosciences, Inc. – Value Analysis (NASDAQ:CALA) : October 5, 2017Calithera Biosciences, Inc. – Value Analysis (NASDAQ:CALA) : October 5, 2017
finance.yahoo.com - October 5 at 11:58 AM
Calithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : October 4, 2017Calithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : October 4, 2017
finance.yahoo.com - October 4 at 12:35 PM
Calithera Biosciences Announces Appointment of Sumita Ray as General Counsel - GlobeNewswire (press release)Calithera Biosciences Announces Appointment of Sumita Ray as General Counsel - GlobeNewswire (press release)
globenewswire.com - October 3 at 4:48 PM
Calithera Biosciences, Inc. (CALA) Major Shareholder Adage Capital Partners Gp, L.L Sells 576,000 SharesCalithera Biosciences, Inc. (CALA) Major Shareholder Adage Capital Partners Gp, L.L Sells 576,000 Shares
www.americanbankingnews.com - September 28 at 7:24 PM
Contrasting Calithera Biosciences (CALA) and Ardelyx (ARDX)Contrasting Calithera Biosciences (CALA) and Ardelyx (ARDX)
www.americanbankingnews.com - September 28 at 6:24 AM
Calithera Biosciences Appoints Blake Wise to Board of Directors - GlobeNewswire (press release)Calithera Biosciences Appoints Blake Wise to Board of Directors - GlobeNewswire (press release)
globenewswire.com - September 22 at 3:53 PM
Calithera Biosciences (CALA) Says CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at SITCCalithera Biosciences (CALA) Says CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at SITC
www.streetinsider.com - September 21 at 4:45 PM
Calithera Biosciences Appoints Blake Wise to Board of DirectorsCalithera Biosciences Appoints Blake Wise to Board of Directors
finance.yahoo.com - September 21 at 4:45 PM
Stocks Under Scanner in the Biotech Space -- Aviragen Therapeutics, Blueprint Medicines, Calithera Biosciences, and ... - PR Newswire (press release)Stocks Under Scanner in the Biotech Space -- Aviragen Therapeutics, Blueprint Medicines, Calithera Biosciences, and ... - PR Newswire (press release)
www.prnewswire.com - September 21 at 11:19 AM
Calithera Biosciences to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners ... - GlobeNewswire (press release)Calithera Biosciences to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners ... - GlobeNewswire (press release)
globenewswire.com - September 20 at 5:40 PM
Calithera Biosciences to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Immuno-Oncology RoundtableCalithera Biosciences to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Immuno-Oncology Roundtable
finance.yahoo.com - September 20 at 5:40 PM
Calithera Biosciences (CALA) Says CB-839 in Combination with ... - StreetInsider.comCalithera Biosciences (CALA) Says CB-839 in Combination with ... - StreetInsider.com
www.streetinsider.com - September 19 at 9:58 PM
Calithera Biosciences Announces CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual MeetingCalithera Biosciences Announces CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
finance.yahoo.com - September 19 at 4:56 PM
Calithera Biosciences, Inc. (CALA) Receives Average Rating of "Hold" from AnalystsCalithera Biosciences, Inc. (CALA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - September 16 at 10:56 PM

SEC Filings

Calithera Biosciences (NASDAQ:CALA) SEC Filings

DateFilerForm TypeView
12/06/2017
3:05 PM
Calithera Biosciences (Issuer)
Molineaux Susan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/06/2017
3:05 PM
Calithera Biosciences (Issuer)
Molineaux Christopher (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing

Social Media

Financials

Calithera Biosciences (NASDAQ:CALA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Calithera Biosciences (NASDAQ CALA) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.